ࡱ> _ Nbjbj 6bb9Er00000DDD8||D7(($zܮ0ܮ00ooo00ooo@6TA}l07 d0oܮܮo7 : 11: Eye Please select a topic: 11.3 Anti-infective eye preparations11.4 Corticosteroids and other anti-inflammatory preparations11.5 Mydriatics and cycloplegics11.6 Treatment of glaucoma11.7 Local anaesthetics11.8 Miscellaneous ophthalmic preparations Changes to the Formulary since previous version (22.8.2013) SectionChangeReason for change11.6ADDED: Dorzolamide hydrochloride/timolol maleate (Cosopt) preservative-free eye drops: new pipette designMHRA Drug Safety Update 11.1 Administration of drugs to the eye Drugs administered as eye drops penetrate directly into the globe through the cornea. Absorption may also occur into the general circulation via conjunctival vessels or from the nasal mucosa after drainage of excess preparation down through the tear ducts; this can produce systemic side-effects. Systemic absorption can be reduced by 'punctal occlusion', i.e. pressing tightly with a finger on the inside corner of the eye for about half a minute after instilling the eye drop. Eye drops should be instilled by pulling down the lower eyelid and putting one drop into the pocket that is formed. The eye should then be closed tightly for about a minute (or see 'punctal occlusion' above). The conjunctival fornix can only accommodate one drop; since any extra will overflow (possibly leading to systemic absorption), only one drop should be used. Eye ointments may be applied to the inside of the lower eyelid when a prolonged action is required. Eye ointments are applied by starting at the inside corner of the eye and squeezing a thin line (about half a centimetre) along the inside of the lower lid, then blinking the eye. Subconjunctival injection may be used to administer anti-infective drugs, mydriatics or corticosteroids for conditions not responding to topical therapy. Soft contact lenses should not generally be worn while using eye drops containing preservatives, or eye ointments. For further information see BNF section 11.9. If using 2 different eye drops, leave a period of about 5 minutes between the two drops. If using drops and ointment, use the drop first then wait 5 minutes before applying the ointment. 11.2 Control of microbial contamination Eye drops in multi-use containers for use in the community should be discarded 4 weeks after opening to avoid contamination. Note: preservative-free preparations may be single-use only or to be discarded 1 week after opening. It is not generally necessary to use separate bottles for each eye (except immediately after eye surgery), but care should be taken to avoid touching the eye(s) during use to avoid contamination. Most drops do not need to be kept in a fridge, unless directed otherwise. Eye drops for theatre use should be provided in single-application containers where possible. If a multi-use container is used it should be discarded after single use. A new unopened bottle of eye drops should be used for each patient. Eye drops in multi-use containers for use on hospital wards should be discarded 1 week after opening to avoid contamination. Note: preservative-free preparations may be single-use only or to be discarded 1 week after opening. It is not generally necessary to use separate bottles for each eye (except immediately after eye surgery), but care should be taken to avoid touching the eye(s) during use to avoid contamination. Most drops do not need to be kept in a fridge, unless directed otherwise. Individual bottles should be provided for each patient. For outpatient-use eye drops should be provided in single-application containers where possible. If multi-use containers are used they should be discarded at the end of each working day or after single-use depending on the infection risk. 11.3 Anti-infective eye preparations Antibacterials Chloramphenicol 0.5% eye drops Chloramphenicol 1% eye ointment Erythromycin 0.5% eye ointment Fusidic acid 1% m/r eye drops (Fucithalmic) Gentamicin 0.3% eye/ear drops Ofloxacin 0.3& eye drops Suggested Doses Bacterial conjunctivitis - Chloramphenicol 0.5% eye drops, 1% eye ointment: drops usually applied 2 hourly for 2 days then 4 times daily for up to 1 week. Ointment usually applied 2-3 times daily, or at night (with drops during the day). Chlamydia conjunctivitis - Azithromycin capsules 250mg; oral suspension 200mg/5mL: 1g as a single dose. Blepharitis - Fusidic acid eye drops m/r 1%: apply twice daily for 2-3 weeks until condition controlled. Corneal ulcers (initiated in hospital) - Ofloxacin 0.3% eye drops: 1 drop in affected eye every 2-4 hours on first 2 days then 4 times daily; max duration of treatment 10 days. Corneal abrasions - Chloramphenicol 1% eye ointment: stat then 3 times daily for 3 days Prescribing notes Bacterial conjunctivitis Most cases of acute bacterial conjunctivitis are self-limiting. Treatment should be given if the condition has not resolved spontaneously after 5 days. Viral conjunctivitis Antibacterials are not helpful in managing viral conjunctivitis. Chlamydia conjunctivitis For proven chlamydial infection, appropriate systemic therapy should be prescribed. Blepharitis Bathing eyes and increased hygiene may be all that is necessary to treat blepharitis. Fusidic acid eye drops have a narrower spectrum of activity than chloramphenicol, and are more expensive. They should therefore be reserved for blepharitis as they are particularly effective against Staphylococcal infection. Corneal ulcers Hospital in-patient first-line treatment of corneal ulcers is cefuroxime 50mg/mL eye drops plus gentamicin 15mg/mL eye drops; patients are usually admitted to hospital for intensive treatment. After discharge, they are given enough drops to last until the next hospital appointment; further supplies are arranged via the hospital pharmacy. An alternative hospital initiated treatment is ofloxacin 0.3% eye drops (Exocin) for small subepithelial infiltrates not affecting the visual axis. Corneal abrasions Corneal abrasions are simply treated with chloramphenicol eye ointment. Neonatal conjunctivitis (significant tissue inflammation with purulent discharge) Swab for bacteria and chlamydia. Initial treatment with chloramphenicol ointment 4 times daily for 1 week. If swabs show chlamydia, change treatment to oral erythromycin 62.5mg 4 times daily for 2 weeks. Remember to also manage and treat parents as appropriate (see  HYPERLINK "http://www.ljf.scot.nhs.uk/exist/xmldb/db/ljf_v2/unified/unified5_d.xml" Chapter 5(d)). Blocked tear duct Watery, intermittently sticky eyes in infants are often due to blocked tear ducts and do NOT require topical antibiotic treatment, unless the eye is red. Simple bathing is all that is needed. Antivirals Aciclovir 3% eye ointment Aciclovir 800mg tablets Dose - Aciclovir 3% eye ointment: apply 5 times daily until at least 3 days after total healing. - Aciclovir tablets 800mg: for herpes zoster infections, 800mg 5 times daily for 7 days. Prescribing notes Topical aciclovir is used for herpes simplex corneal infections, under hospital supervision. Oral aciclovir should be prescribed immediately for ophthalmic zoster. 11.4 Corticosteroids and other anti-inflammatory preparations Corticosteroids Betamethasone 0.1% eye ointment Betamethasone 0.1% eye/ear/nose drops Dexamethasone 0.1% (Maxidex) Prednisolone 0.5% eye/ear drops and 0.5% minims Prednisolone 1% eye drops Combinations Betnesol-N eye/ear drops Maxitrol eye drops Dose - Betamethasone 0.1% eye/ear/nose drops: often used 4-6 times daily postoperatively, but may be used from as little as once every second day to as often as every hour depending on condition. - Betamethasone 0.1% eye ointment: apply 2-4 times a day. - Dexamethasone 0.1% eye drops: often used 4-6 times daily but in severe conditions may be used every 30-60mins until controlled then reduce frequency. - Prednisolone 0.5% eye/ear drops & minims: apply 1 drop 2-4 times a day. - Prednisolone 1% eye drops: apply 1 drop 2-4 times a day. - Betnesol-N eye drops (betamethasone 0.1%, neomycin 0.5%): apply eye drops every 1-2 hours until controlled then reduce frequency - Maxitrol eye drops (dexamethasone 0.1%,neomycin 0.35%, polymyxin B sulphate 6000units/ml): apply eye drops upto six times a day or more frequently if required. Prescribing notes Corticosteroid eye preparations should normally only be used under the supervision of an ophthalmologist because (a) their use may mask and worsen infection (especially herpes simplex keratitis), (b) they may cause glaucoma in some patients, and (c) long-term use can cause cataract. Betamethasone 0.1% with neomycin 0.5% is used when an antibiotic is also needed. Sometimes neomycin causes allergy in which case chloramphenicol drops may be prescribed along with betamethasone. Preservative-free preparations are available for patients suspected to be intolerant of preservatives. Other anti-inflammatory preparations Sodium cromoglicate 2% eye drops Dose - Sodium cromoglicate 2% eye drops: apply 4 times daily. Prescribing notes Sodium cromoglicate is used to treat allergic conjunctivitis. It has a prophylactic action and must be used regularly even when symptoms improve. 11.5 Mydriatics and cycloplegics Antimuscarinics Atropine sulphate 1% single use eye drops Atropine sulphate 1% eye drops Cyclopentolate 0.5% single use eye drops Cyclopentolate 1% single use eye drops Cyclopentolate 1% eye drops Tropicamide 0.5% single use eye drops Tropicamide 0.5% eye drops Dose - Atropine sulphate 1% eye drops: usually once or twice daily. - Cyclopentolate 1% eye drops: 2-3 times daily. - Tropicamide 0.5% eye drops: 1 drop. Prescribing notes Antimuscarinics dilate the pupil (mydriasis) and paralyse the ciliary muscle (cycloplegia). They are used in the treatment of anterior uveitis. Atropine is the most potent and has the longest duration of action (7 days or more). Cyclopentolate is less potent and of shorter duration (up to 24 hours). Contact dermatitis occurs relatively frequently when atropine is used in the long term. Tropicamide is short-acting (up to 3 hours) and is a useful mydriatic prior to examining the eye. It can cause blurred vision and patients should not drive until this has settled. The BNF advises caution as mydriasis may precipitate acute angle-closure glaucoma in a very few patients usually aged over 60 years and hypermetropic, who are predisposed to the condition because of a shallow anterior chamber. However, the risk is so minimal that this should not be regarded as a contra-indication to its use. Paediatric uses Cyclopentolate 1% drops are used for refraction and fundus examination in children. Atropine 1% eye ointment is used for refraction and fundus examination in children with darkly pigmented irises. Systemic absorption may occasionally lead to facial flushing. Atropine 1% eye drops may be used once daily in the "good" eye in patients with a lazy eye (as an alternative to wearing an eye patch) for 1-3 months according to response. Treatment should be reviewed regularly. Sympathomimetics Phenylephrine 2.5% minims Dose - Phenylephrine 2.5% eye drops Minims: 2-3 times daily. 11.6 Treatment of glaucoma Open-angle glaucoma and treated angle-closure glaucoma are not contra-indications to the use of oral drugs that have anticholinergic effects. Miotics Pilocarpine 1%, 2%, and 4% eye drops Dose - Pilocarpine 1%, 2% or 4% eye drops: usually applied four times daily. Prescribing notes Pilocarpine causes a small pupil which can compromise visual acuity. Headache is a frequent symptom in the first fortnight of treatment. Four times a day application can be difficult for elderly people. Sympathomimetics Brimonidine 0.2% eye drops Dose - Brimonidine 0.2% eye drops: instil twice daily. Prescribing notes Brimonidine can cause allergic conjunctivitis. It should not be used with tricyclic antidepressants or MAOIs, or in children under 5 years. Beta-blockers Betaxolol 0.5% eye drops Carteolol 1% and 2% eye drops Timolol 0.25% and 0.5% eye drops Timolol LA 0.25% and 0.5% eye drops Dose - Timolol 0.25% eye drops: instil twice daily. - Timolol LA 0.25% and 0.5% eye drops: instil once a day. - Carteolol 1% and 2% eye drops: instil twice daily. - Betaxolol 0.5% eye drops: instil twice daily. Prescribing notes Systemic absorption can follow topical application and contra-indications are therefore asthma, bradycardia and congestive heart failure. This applies to all topical beta-blockers. A long-acting once daily formulation (Timoptol-LA) is available for patients who have a problem with compliance. Timolol 0.5% eye drops have no advantage over 0.25% eye drops. Carbonic anhydrase inhibitors and systemic drugs Acetazolomide 250mg tablets Acetazolomide 500mg injection Brinzolamide 10mg/ml eye drops Dorzolamide 2% eye drops Cosopt eye drops Dose - Brinzolamide eye drops 10mg/ml: used alone, apply twice daily increased to three times daily if necessary. - Dorzolamide eye drops 2%: used alone, apply three times daily; with topical beta-blocker, apply twice daily. - Cosopt eye drops (dorzolamide 2%, timolol 0.5%):apply twice daily. - Acetazolamide tablets 250mg: 0.25-1g daily in divided doses. - Acetazolamide sodium injection 500mg: by intravenous injection. Prescribing notes Dorzolamide can cause allergic conjunctivitis. Allergy can occur. Dorzolamide and acetazolamide are contra-indicated in patients allergic to sulphonamides. Cosopt eye drops should be reserved for compliance purposed in those patients receiving dorzolamide, timolol, and a third eye drop preparation. Acetazolamide can be given orally but long-term use is not advisable because of side-effects. These include metabolic acidosis and electrolyte imbalance; renal calculi; paraesthesia; headache and malaise; gastro-intestinal upset; blood dyscrasias. MHRA Drug Safety Update Dorzolamide hydrochloride/timolol maleate (Cosopt) preservative-free eye drops: new pipette design Article date: Marchy 2014 Summary In December 2013 we reported eye injuries caused by the pipette design of Cosopt preservative-free eye drops. Because of these injuries, a new pipette design was introduced in February 2014 as an interim measure. The instructions for using the new design are enclosed in the product packaging. The old pipette design is now being withdrawn. Please see further guidance on the MHRA website, including an updated Patient Information Leaflet and detailed instructions for use. Link:  HYPERLINK "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON392872" http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON392872 Prostaglandin analogue Bimatoprost 300micrograms/ml eye drops Bimatoprost 300micrograms/ml & Timolol 5mg/ml eye drops (Ganfort) Latanoprost 50 micrograms/ml eye drops Latanoprost 50 micrograms/ml & Timolol 5mg/ml eye drops (Xalacom) Dose - Bimatoprost eye drops 300micrograms/mL: used at night. - Bimatoprost/Timolol eye drops (Ganfort): used once daily - Latanoprost eye drops 50micrograms/mL: used at night. - Latanoprost/Timolol eye drops (Xalacom): used once daily Prescribing notes Prostaglandin analogues may cause an increase in brown iris pigment. Following cataract surgery they can cause macular oedema. Prostaglandin analogues may initially cause conjunctival hyperaemia. This should not be painful and wears off as the eye becomes accustomed to it (usually in about 4 weeks). Combination drops may be useful (e.g. Ganfort or Xalacom) as there is no significant additional cost compared with the individual components and it allows the patient to administer fewer drops. 11.7 Local anaesthetics Tetracaine hydrochloride (Amethocaine hydrochloride) 1% single use eye drops Dose - Tetracaine 1% eye drops (Minims): 1 drop repeated if necessary. Prescribing notes Tetracaine (amethocaine) eye drops produce a more profound anaesthesia than oxybuprocaine and are suitable for use before minor surgical procedures. It has a temporary disruptive effect on the corneal epithelium. Local anaesthetic drops should never be used for the symptomatic control of pain because of corneal epithelium toxicity. 11.8 Miscellaneous ophthalmic preparations Fluorescein sodium 1% minims Dose - Fluorescein eye drops 1% or 2% (Minims Fluorescein Sodium). Tear deficiency, ocular lubricants and astringents Hypromellose 0.3% eye drops Carbomer 980 (Viscotears) eye drops Liquid Paraffin (Lacri-lube) eye ointment Sodium chloride 0.9% single use eye drops (Minims saline) Dose - Hypromellose 0.3% eye drops: may need to be instilled frequently e.g. hourly, for adequate relief. - Carbomer 980 (Viscotears) 0.2% eye drops: this is a gel and may be instilled 3-4 times daily. - Sodium chloride 0.9% eye drops (Minims saline): use as directed - Liquid Paraffin (Lacri-Lube) white soft paraffin 57.3%, liquid paraffin 42.5%, wool alcohols 0.2%: use as directed Prescribing notes These preparations are available over-the-counter. Chronic soreness of the eyes due to reduced / abnormal tear secretion often responds to tear replacement therapy. The severity of the condition and patient preference will often guide the choice of preparation. Frequent instillation of drops (e.g. hourly hypromellose) may cause a sensitivity reaction to the preservative in the drops. There are several preservative-free artificial tear preparations available. Hypromellose eye drops are the traditional choice of treatment for tear deficiency. It is the cheapest and the least viscous. Lacri-lube is usually applied at night. It can however be used during the day in cases of persistent corneal epithelial erosion, but it will blur the vision. All available lubricant eye ointments contain lanolin.     Red = Hospital use only Green = GP & Hospital use. Drugs not classified as Red, Amber or Green + are classified as Green by default Amber 1 = Drugs with shared care agreement Green + = Initiated by Hospital specialist only Gateshead Health NHS Foundation Trust Page  PAGE 8 of  NUMPAGES 12 Date: 17.3.2014 Drug Formulary CD    6 9 : ? A B c d h i n p ɹɹɹɹɹɹ~tj~`jh]"CJOJQJhhCJOJQJhxCJmH sH hxCJOJQJh]"5CJOJQJhh5CJOJQJhx5CJOJQJhsCJOJQJ hsCJhsB*CJOJPJQJphhs5CJOJQJhsB*OJQJphhsB*CJOJQJphhsOJQJhsCJOJQJ D~pkd$$IfT0Z xx04 aT $$Ifa$$a$ $$Ifa$pkd$$IfT0Z xx04 aT   5 A B J Q c xxoeee dd$Ife^egdx $e^ea$gdx hdd^hpkd*$$IfT0Z xx04 aTc d i k]PP dd$Ifgd]" *dd$Ifkd$$IflF :I(F F/ F  t06    44 lBahytxp  w{&'S~rˆˆaP!hhhsB*CJOJQJph!hhhsB*CJOJQJphhs0JCJOJQJhsOJQJhsCJOJQJhyh5CJOJQJ\hs5CJOJQJ\hs5CJOJQJ\h aCJOJQJhsCJOJQJhsCJOJQJhxCJmH sH h]"CJOJQJhxCJOJQJh]"h]"CJOJQJ  e wki]]]]]]Xi & F & F dd[$\$kdn$$IflF :I(F F/ F  t06    44 lBahytx |'Tr[ dexy, & Fdd[$\$` hdd^h & Fdd & F0STqr  [ 0Acdxy,@9;I5F ȾȮȮߝȐh a6CJOJQJ] hs5CJOJPJQJ\^Jhs56CJOJQJ\]h aCJOJQJhsCJOJQJhs6CJOJQJ]hs5CJOJQJ\hsCJOJQJhsCJOJQJ6,BW9:;K5H R Y!l!," hdd^h & Fdd[$\$ & Fdd[$\$ & Fdd[$\$ & Fdd[$\$ & Fdd[$\$ & Fdd[$\$ G!H!T!U!Y!j!,"9":"S"U"l"m"}"~""""""'#:#;###$ $0$1$P$Q$v$w$¸|縮t¸gZh ahsCJOJQJh7h7CJOJQJhsOJQJ hs5CJOJPJQJ\^Jhs5CJOJQJ\h7CJOJQJh7CJOJQJhsCJOJQJhsCJOJQJhs0JCJOJQJhs6CJOJQJ]hs0JCJOJQJhsCJOJQJjhsCJOJQJU","-"."9":"U"m"r"'#(#;#### $!$1$Q$w$$$ & Fdddd & Fdd & Fdd[$\$h`h hdd^h & Fddw$$$$$$$$$%%%%% %-%.%F%%%%%%&ӿӦwmwm`mVIV>>>>>>韉pU4h1@h]"B*CJOJQJ\^JaJmH phUUUsH 0h]"h]"5B*CJOJQJ^JmH phsH *h]"5B*CJOJQJ^JmH phsH 0h1@h]"5B*CJOJQJ^JmH phsH hs5CJOJQJ\h76CJOJQJ]h75CJOJQJ\h7CJOJQJhsCJOJQJhs6CJOJQJ];<"<|<=>>>>>>@@A A!A"A9Addh-DM }^hgd]"$h-DM }^ha$gd]" & F'dd[$\$ & F&dd[$\$ & F%dd[$\$ & F$dd[$\$>>>>>>@@@@@@@@AͱwkR;R&(h}5h]"0JCJOJQJ^JmH sH -h]"h]"B*CJOJQJ^JmH ph"""sH 0jh]"B*CJOJQJU^JmH ph"""sH h]"CJOJQJ^Jh]"h]"CJOJQJ^J'h]"B*CJOJQJ^JmH ph"""sH -h1@h]"B*CJOJQJ^JmH ph"""sH 7h1@h]"5B*CJOJQJ\^JaJmH phUUUsH 4h1@h]"B*CJOJQJ\^JaJmH phUUUsH .h]"B*CJOJQJ\^JaJmH phUUUsH AA A!A"A8A9A_A`AAAAA BBB B!B;BNBbBcBɿɢrhh[ND7DNDhK6CJOJQJ]hKCJOJQJhK5CJOJQJ\hs5CJOJQJ\hsCJOJQJ!hxAhKB*CJOJQJphhKB*CJOJQJph!hKhxAB*CJOJQJph!hxAhxAB*CJOJQJphhs0JCJOJQJh]"CJOJQJhsCJOJQJ'h]"B*CJOJQJ^JmH ph"""sH 0jh]"B*CJOJQJU^JmH ph"""sH 9A`AAABBLBBBBCC>DEEhEmEEEFGG & F+dd[$\$ & F*dd[$\$ & F dd & F!dd & F!dd[$\$dd & F ddcBwBBBBBBBBBBBCC&C'CpCtCCC>DEEEEgEhEmEoEyEzEEEEGG?G@G]GpGGGGŸŸ鮤ŸŮ|lhs56CJOJQJ\]hs5B*CJOJQJphhs5B*CJOJQJphhsOJQJhsCJOJQJhsCJOJQJhs6CJOJQJ]hsCJOJQJhs5CJOJQJ\hK5CJOJQJ\hKCJOJQJhK6CJOJQJ]*G?G@G]GbGGGGGH@H{HHFIIIJFJKbL8M9M & F.dd[$\$ & F-dd[$\$ & F,dd[$\$dd & F dd & F38^8GGGGGGHH?H@HiHzH{HHHHHHHHIIHIWIXIyIIIIIJJaLbL7M8M9M:MM?MAMBMDMEM]MMM$N%NNNNNNNEM]MMMMMM%NaNbNhNiNjNkNoNpNzN{N}N~NNNNNNNNN߿rrfZfVRNhshp3h(h]"CJOJQJ^JhICJOJQJ^J!h]"CJOJQJ^JmHnHujh(CJOJQJU^Jh(CJOJQJ^Jh(B*CJOJQJ^JphhhB*CJOJQJ^Jphh(B*CJOJQJ^Jphfh*B*CJOJQJ^Jphh(B*CJOJQJ^Jphh(B*CJOJQJ^Jph4P P &P . A!S"S#S$S% $$If!vh#vx:V 0,5x/ 44 T$$If!vh#vx:V 0,5x/ 44 T$$If!vh#vx:V 0,5x/ 44 T$$Ifh!vh#v #v/ #v :V l t065 5/ 5 / Bahytx$$Ifh!vh#v #v/ #v :V l t065 5/ 5 / Bahytx^ 2 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~_HmH nH sH tH <`< NormalCJ_HmH sH tH N@N  Heading 1$dd@&5CJOJQJ\P@"P  Heading 2 dd@&5B*CJ$OJPJQJP@2P  Heading 3 dd@&5B*CJOJPJQJDA`D Default Paragraph FontVi@V  Table Normal :V 44 la (k (No List *W@* Strong5\P^@P Normal (Web) ddB*CJOJPJQJ6U@6 Hyperlink >*B*ph4"4 Header  !4 @24 Footer  !H@BH ; Balloon TextCJOJQJ^JaJPK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭V$ !)O^rC$y@/yH*񄴽)޵߻UDb`}"qۋJחX^)I`nEp)liV[]1M<OP6r=zgbIguSebORD۫qu gZo~ٺlAplxpT0+[}`jzAV2Fi@qv֬5\|ʜ̭NleXdsjcs7f W+Ն7`g ȘJj|h(KD- dXiJ؇(x$( :;˹! I_TS 1?E??ZBΪmU/?~xY'y5g&΋/ɋ>GMGeD3Vq%'#q$8K)fw9:ĵ x}rxwr:\TZaG*y8IjbRc|XŻǿI u3KGnD1NIBs RuK>V.EL+M2#'fi ~V vl{u8zH *:(W☕ ~JTe\O*tHGHY}KNP*ݾ˦TѼ9/#A7qZ$*c?qUnwN%Oi4 =3N)cbJ uV4(Tn 7_?m-ٛ{UBwznʜ"Z xJZp; {/<P;,)''KQk5qpN8KGbe Sd̛\17 pa>SR! 3K4'+rzQ TTIIvt]Kc⫲K#v5+|D~O@%\w_nN[L9KqgVhn R!y+Un;*&/HrT >>\ t=.Tġ S; Z~!P9giCڧ!# B,;X=ۻ,I2UWV9$lk=Aj;{AP79|s*Y;̠[MCۿhf]o{oY=1kyVV5E8Vk+֜\80X4D)!!?*|fv u"xA@T_q64)kڬuV7 t '%;i9s9x,ڎ-45xd8?ǘd/Y|t &LILJ`& -Gt/PK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 0_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!0C)theme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK] F  qqqtp S w$&,37:>AcBGEMN(-02468:=>@ACEG c ,,"$<+;/l4"7;9AG9MN)*+,./13579;<?BDFGT889FXX(/16ADt!8@0(  B S  ?p{U^ ' + ##$$$$%+5+B,M,111222+272223 33%3*31333|4444446*696@6J6P6666699D9`9k99999999999: :: :N:Y:Z:a:n:u:::::::::;;d<k<p<w<'@,@AAbDgD9E;EE?EAEBEDEEEFFr.x.73=3Z:f:::9E;EE?EAEBEDEEEFF333333Dw l 'Te,B;K5HTUr(;!vw\ n "#<#N##$;$$$$$ %&D&8)I)*N**$+%+6+:,V,V,l,,,------ ..'//000111)2334"456!9_99::;U;;====?b??@{@{@BB7DaDE8E9E9E;EE?EAEBEDEEEEEEEFFFFFFFF $$$$V,V,----6!9<={@{@8E9E9E;EE?EAEBEDEEEEEEEFFFFFF3YUYm!YW$Cf < YDY]mZh4YV\nY<&Y4Yu#*}2#*'?k(YnS*Y(b/aB3Y*7Y"+7Yq 8Y@f9Yv9 X}U9Y^A%;`8za; ht!=Yl>Y4-?F>rAYXM2B0w FYAHYJ(IYS8LYcLY5 MbU8ZQYKUXEWY YH:T`~N5bxqdY>hYIJn xqYwoqY~wsY1AvYqHxY?H{Y^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(h^`CJOJQJo(h ^`OJQJo(oh pp^p`OJQJo(h @ @ ^@ `OJQJo(h ^`OJQJo(oh ^`OJQJo(h ^`OJQJo(h ^`OJQJo(oh PP^P`OJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(h ^`OJQJo(h ^`OJQJo(oh pp^p`OJQJo(h @ @ ^@ `OJQJo(h ^`OJQJo(oh ^`OJQJo(h ^`OJQJo(h ^`OJQJo(oh PP^P`OJQJo(h^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(h^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(h^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(h^`CJOJQJo(h ^`OJQJo(oh pp^p`OJQJo(h @ @ ^@ `OJQJo(h ^`OJQJo(oh ^`OJQJo(h ^`OJQJo(h ^`OJQJo(oh PP^P`OJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(h^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(h^`CJOJQJo(h ^`OJQJo(oh pp^p`OJQJo(h @ @ ^@ `OJQJo(h ^`OJQJo(oh ^`OJQJo(h ^`OJQJo(h ^`OJQJo(oh PP^P`OJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(h^`CJOJQJo(pp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(h^`CJOJQJo(h ^`OJQJo(oh pp^p`OJQJo(h @ @ ^@ `OJQJo(h ^`OJQJo(oh ^`OJQJo(h ^`OJQJo(h ^`OJQJo(oh PP^P`OJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(h^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(h^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(h^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(3V\N5bKUIJn^A%;4-?W$ Yza;T`u#}2#l>cL?H{w F < J(I*7U9aB3>hwoqqHx1AvD@f9YUh4!=<&"+7nS*qdm!EW?k(~wsU8ZQ xq4AHrAq 8S8L]v9XM2B5 M(b/33Ї2jX[,v XysNʢxn*.EOsJJRTھ~blzMrШflP~8M.hrY yb!i rcBN3"vӶi2WWXj hs.        ăL.VN| Xa.d}@Y0Nڌ#g(<bT#zR<2Eqy(HJ\l@1 lbdņ2b.P(jl~PɦV&PFF\?HZ'L̨̐:_RKdԼT{GndlljpkLSv          xD&+~&T>nNNPDTmze0Vd~\8L7NR:x~'6Rf>d-,Δm,lC<,*n0Fɔ65~s"fT*j{(/062        j$9j]vl4ӄ T80X(a, 8چ`zdy0*P0.6\Nf$7sdPWLe(G0I|ʩ% lHU`̂{F|9d&ľj ՘RV\j&@0:DtNjL7>V* 2         @xV^z.0|S :눏 .tF(HPkVxxERLdh.d'00RV\qdLdgZt`r B&Ķܻb&kPƼ҈4..C:F?@ABCDEFGHJKLMNOPRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~Root Entry FdAData I1TableQWordDocument6SummaryInformation(DocumentSummaryInformation8CompObjr  F Microsoft Word 97-2003 Document MSWordDocWord.Document.89q